ING Groep NV lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,043 shares of the company’s stock after selling 12,933 shares during the period. Johnson & Johnson makes up approximately 2.7% of ING Groep NV’s investment portfolio, making the stock its 9th biggest holding. ING Groep NV’s holdings in Johnson & Johnson were worth $63,341,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Dumont & Blake Investment Advisors LLC increased its holdings in Johnson & Johnson by 0.3% during the fourth quarter. Dumont & Blake Investment Advisors LLC now owns 20,796 shares of the company’s stock valued at $3,033,000 after buying an additional 71 shares during the period. DE Burlo Group Inc. increased its holdings in Johnson & Johnson by 3.9% during the fourth quarter. DE Burlo Group Inc. now owns 1,871 shares of the company’s stock valued at $273,000 after buying an additional 71 shares during the period. Modus Advisors LLC increased its holdings in Johnson & Johnson by 2.0% during the first quarter. Modus Advisors LLC now owns 3,666 shares of the company’s stock valued at $481,000 after buying an additional 73 shares during the period. AlphaMark Advisors LLC increased its holdings in Johnson & Johnson by 1.3% during the fourth quarter. AlphaMark Advisors LLC now owns 5,799 shares of the company’s stock valued at $846,000 after buying an additional 75 shares during the period. Finally, Capital Financial Planning LLC increased its holdings in Johnson & Johnson by 3.6% during the fourth quarter. Capital Financial Planning LLC now owns 2,192 shares of the company’s stock valued at $320,000 after buying an additional 76 shares during the period. 67.66% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald restated a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. Credit Suisse Group restated a “buy” rating and issued a $161.00 target price on shares of Johnson & Johnson in a research note on Tuesday, April 28th. UBS Group downgraded shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their target price for the company from $163.00 to $160.00 in a research note on Tuesday, April 28th. Bank of America upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their target price for the company from $150.00 to $175.00 in a research note on Wednesday, April 22nd. Finally, Argus restated a “buy” rating and issued a $155.00 target price (down from $165.00) on shares of Johnson & Johnson in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $163.47.

In other Johnson & Johnson news, Director William D. Perez bought 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the transaction, the director now directly owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.

NYSE:JNJ opened at $144.37 on Friday. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00. The firm has a fifty day simple moving average of $146.81 and a 200-day simple moving average of $142.30. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $386.52 billion, a P/E ratio of 19.10, a PEG ratio of 3.19 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The business’s revenue for the quarter was up 3.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.10 earnings per share. Equities analysts forecast that Johnson & Johnson will post 7.68 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a dividend of $1.01 per share. The ex-dividend date of this dividend is Friday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s payout ratio is currently 43.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Quiet Period

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.